Trial Profile
A retrospective study assessing Clinical efficacy, baseline and emergent resistance in multidrug-resistant Pseudomonas aeruginosa (MDR-Pa) infections treated with Ceftolozane/tazobactam
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018